Table 3 Time-to-onset analysis for signals.

From: A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database

 

TTO (day)

Weibull distribution

Failure type

Variable

Case, N

Median (IQR)

α(95%CI)

β(95%CI)

 

Total

9502

145(33–520)

292.68(282.52–302.84)

0.61(0.60–0.62)

Early failure

Male

2835

148(35–560)

303.97(284.70–323.24)

0.61(0.60–0.63)

Early failure

Females

6578

144(32–504)

287.68(275.66–299.70)

0.61(0.60–0.62)

Early failure

Children

707

95(28–383)

203.79(178.13–229.45)

0.62(0.58–0.65)

Early failure

Adult

5912

140(32–489)

281.32(268.91–293.73)

0.61(0.60–0.62)

Early failure

Elderly

1563

182(40–732)

379.06(345.86–412.26)

0.60(0.57–0.62)

Early failure

Back to article page